CD73, together with CD39, plays an important role in promoting immunosuppression through the pathway degrading ATP into adenosine, which has a significant effect on the tumor microenvironment. Theses cell surface enzymes have emerged as novel therapeutic targets to enhance antitumor immune responses across a wide range of tumors.
TIGIT - more clones
The complexity of the TIGIT axis in immune oncology has increased the demand for different antibody clones targeting different immunogenic motifs.
CD226 - different clones
CD226 and TIGIT share ligands and binding of CD155 and CD112 has different impact on T cell responses. This complexity may be investigated with different antibody clones targeting different immunogenic motifs.
CD155 - different clones
CD155 acts as the ligand for both costimulatory receptor CD226 and coinhibitory receptor TIGIT and CD96 on natural killer and T cells. This complexity may be investigated with different antibody clones targeting different immunogenic motifs.
TIGIT - clone TG1
Clone TG1 immunohistochemistry allows the identification of invading TIGIT positive T-cells in routine fixed FFPE human tumor tissues.
Tumor IHC marker
p16- clone JAP16
Clone JAP16 has been validated for detection of p16 INK4 in routine fixed FFPE tissues with focus on gynecological pathology.
BSEP - clone JAP11
CD138 - clone JASY1
PAX8 - clone JAX8
PD-1 - clone JAD1
PD-L1 - clone JAL1
MUC-5 - clone JAC5